Literature DB >> 30696620

Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.

Linda von Hoff1, Eva Kärgel1, Vedran Franke2, Erik McShane3, Kathrin W Schulz-Beiss4, Giannino Patone5, Nikolai Schleussner6,7, Marina Kolesnichenko1, Norbert Hübner5, Oliver Daumke4, Matthias Selbach3, Altuna Akalin2, Stephan Mathas6,7, Claus Scheidereit1.   

Abstract

Persistent NF-κB activation is a hallmark of the malignant Hodgkin/Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL). Genomic lesions, Epstein-Barr virus infection, soluble factors, and tumor-microenvironment interactions contribute to this activation. Here, in an unbiased approach to identify the cHL cell-secreted key factors for NF-κB activation, we have dissected the secretome of cultured cHL cells by chromatography and subsequent mass spectrometry. We identified lymphotoxin-α (LTA) as the causative factor for autocrine and paracrine activation of canonical and noncanonical NF-κB in cHL cell lines. In addition to inducing NF-κB, LTA promotes JAK2/STAT6 signaling. LTA and its receptor TNFRSF14 are transcriptionally activated by noncanonical NF-κB, creating a continuous feedback loop. Furthermore, LTA shapes the expression of cytokines, receptors, immune checkpoint ligands and adhesion molecules, including CSF2, CD40, PD-L1/PD-L2, and VCAM1. Comparison with single-cell gene-activity profiles of human hematopoietic cells showed that LTA induces genes restricted to the lymphoid lineage, as well as those largely restricted to the myeloid lineage. Thus, LTA sustains autocrine NF-κB activation, impacts activation of several signaling pathways, and drives expression of genes essential for microenvironmental interactions and lineage ambiguity. These data provide a robust rationale for targeting LTA as a treatment strategy for cHL patients.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30696620     DOI: 10.1182/blood-2018-08-871293

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma.

Authors:  Zhihui Song; Wei Wei; Wenming Xiao; Essel D Al-Saleem; Reza Nejati; Liqi Chen; Jiejing Yin; Joseph Fabrizio; Michael N Petrus; Thomas A Waldmann; Yibin Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-02       Impact factor: 12.779

Review 2.  Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer.

Authors:  Valli De Re; Laura Caggiari; Mariangela De Zorzi; Valentina Fanotto; Gianmaria Miolo; Fabio Puglisi; Renato Cannizzaro; Vincenzo Canzonieri; Agostino Steffan; Piero Farruggia; Egesta Lopci; Emanuele S G d'Amore; Roberta Burnelli; Lara Mussolin; Maurizio Mascarin
Journal:  Infect Agent Cancer       Date:  2020-06-23       Impact factor: 2.965

3.  Construction and Validation of a Newly Prognostic Signature for CRISPR-Cas9-Based Cancer Dependency Map Genes in Breast Cancer.

Authors:  Xin Yan; Sai-Nan You; Yan Chen; Ke Qian
Journal:  J Oncol       Date:  2022-01-19       Impact factor: 4.375

4.  Multitargeting Effects of Calebin A on Malignancy of CRC Cells in Multicellular Tumor Microenvironment.

Authors:  Constanze Buhrmann; Ajaikumar B Kunnumakkara; Aviral Kumar; Marek Samec; Peter Kubatka; Bharat B Aggarwal; Mehdi Shakibaei
Journal:  Front Oncol       Date:  2021-09-29       Impact factor: 6.244

5.  Calebin A Potentiates the Effect of 5-FU and TNF-β (Lymphotoxin α) against Human Colorectal Cancer Cells: Potential Role of NF-κB.

Authors:  Constanze Buhrmann; Ajaikumar B Kunnumakkara; Bastian Popper; Muhammed Majeed; Bharat B Aggarwal; Mehdi Shakibaei
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

6.  JAK3 and TYK2 Serve as Prognostic Biomarkers and Are Associated with Immune Infiltration in Stomach Adenocarcinoma.

Authors:  Lingkai Meng; Ling Ding; Yue Yu; Wang Li
Journal:  Biomed Res Int       Date:  2020-09-19       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.